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Abstract: Nutritherapy seeks to prevent or correct disease by the use of nutritional supplements including
vitamins, trace elements, or macronutrients. This chapter of the ”Les Entretiens du Carla” reviews
the potential of nutritherapy for the prevention or improvement of sarcopenia, which is the progressive
reduction in muscle mass and muscle strength prevalent in late-life. It is critical that we review nutrients
and their potential to maintain muscle mass and strength which ultimately will help minimize falls and
fractures among the older population. Evidence from randomized-controlled trials will be reviewed for
muscle mass as well as important sarcopenia-related endpoints including lower extremity strength and
function, as well as falls and fall-related fractures. This chapter will focus on vitamin D as a compelling
strategy with evidence for strength gain, fall and fracture prevention from double-blind randomized
controlled trials. The other strategy discussed is increased protein intake although longer-term trials
and evidence for clinically important endpoints are limited. Today, there is no consistent data on other
micronutrients or macronutrients with an established potential to combat sarcopenia.
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Introduction
Nutritherapy seeks to prevent or correct disease by the use of
nutritional supplements including vitamins, trace elements, or
macronutrients. This chapter of the “Les Entretiens du Carla”
reviews the potential of nutritherapy for the prevention or
improvement of sarcopenia, which is the progressive reduction
in muscle mass and muscle strength prevalent in late-life. It is
critical that we review nutrients and their potential to maintain
muscle mass and strength which ultimately will help minimize
falls and fractures among the older population. Evidence from
randomized-controlled trials will be reviewed for muscle mass
as well as important sarcopenia-related endpoints including
lower extremity strength and function, as well as falls and fall-
related fractures. This chapter will focus on vitamin D as a
compelling strategy with evidence for clinically important
endpoints. The other strategy discussed is increased protein
intake although longer-term evidence and evidence for
clinically important endpoints are limited.  Today, there is no
consistent data on other micronutrients or macronutrients with
an established potential to combat sarcopenia. 
The sarcopenia challenge in fracture prevention 
at older age
Critical for the understanding and prevention of fractures at
later age is their close relationship with sarcopenia (muscle
weakness) (1), and falling (2, 3). Over 90% of fractures occur
after a fall and fall rates increase with age (4) and poor muscle
strength or function (Figure 1) (4). Notably, anti-resorptive
treatment alone may not reduce fractures among individuals 80
years and older in the presence of non-skeletal risk factors for
fractures, such as muscle weakness and falling, despite an
improvement in bone metabolism (5). Moreover, low muscle
strength is an independent predictor of functional decline (6)
and poor bone quality (7) among older adults.  
Today, vitamin D is the only known strategy and only
nutritherapy that has the comprehensive potential of strength
improvement, as well as evidence for fall and fracture
prevention among older individuals as documented in
randomized controlled trials (RCTs).  
Figure 1
Fall-fracture construct 
Adapted from Bischoff-Ferrari et al.; Chapter Prevention of Falls in Treatment of
Osteoporosis; 2008 Seventh Edition of The Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism (American Society of Bone and Mineral Research). The
graph illustrates the pivotal contribution of sarcopenia to the fall and fracture construct.
Nutritherapy with vitamin D may address each component of the fall-fracture construct as
illustrated in Figure 1, including sarcopenia (63), strength (35), balance (38), lower
extremity function (33, 34), falling (37, 39 ), bone density (27, 71), the risk of hip and non-
vertebral fractures (51 ), and the risk of nursing home admission (72 ). 
Vitamin D: prevalence of deficiency and risk factors
Prevalence of severe vitamin D deficiency (25-
hydroxyvitamin D levels < 30 nmol/l or < 12 ng/ml) is still high
in older individuals, while desirable vitamin D levels of at least
75 nmol/l (30 ng/ml) for optimal muscle and bone health is
reached by less than 30% of the US older population and less
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than 20% by the European older population (8, 9).  
A 1999 landmark publication in the Journal of the American
Medical Association (JAMA) by LeBoff and colleagues
documented a 50% prevalence of severe vitamin D deficiency
among postmenopausal women admitted with acute hip fracture
(serum 25(OH)D levels < 30 nmol/l)[10]. The authors
suggested in 1999 that heightened awareness is necessary to
ensure adequate vitamin D nutrition, especially as vitamin D
deficiency is preventable. The high prevalence of severe
vitamin D deficiency among hip fracture patients has been
confirmed in the early and late nineties by several studies from
Europe (11-19). According to Swiss data published in 2008, the
prevalence of severe 25(OH)D deficiency is still significant and
basically unchanged compared to earlier data with a more than
50% prevalence of severe deficiency among hip fracture
patients admitted from home and a 75% prevalence of severe
deficiency among those admitted from institutions (20).
Notably, less than 10% of 222 hip fracture patients investigated
had any dose of vitamin D supplementation upon admission to
acute care (20). 
Most vulnerable to low vitamin D levels are older
individuals (21, 22), individuals living in northern latitudes
with prolonged winters (23, 24), obese individuals (25), and
African Americans of all ages (26-28). Older individuals are at
high risk of low vitamin D status because of the decreased
production of vitamin D in the skin with age after sun exposure,
which is 4-fold lower compared to younger adults (29).
Furthermore, among older adults and within Europe lowest 25-
hydroxyvitamin D levels are measured in Southern Europe
(30), which may be explained by sun avoidance and sun
protection at older age. Finally, nutritional sources of vitamin D
are rare and are mostly limited to fatty fish, such as salmon,
which is not regularly consumed in 2 servings and each day
(31). Additionally, food fortification with vitamin D is not
practiced in Europe as it is in the US, although the small benefit
of about 200 IU vitamin D through consumption of fortified
milk or orange juice in the US is small and did not prevent a
further decline in 25- hydrocyvitamin D status among US
adults as documented in the newest NHANES study (oral
presentation of Prof. Bess Dawson-Hughes; IANA conference
Boston 2007). 
Vitamin D: its role in muscle health 
In humans, four lines of evidence support a role of vitamin D
in muscle health and the prevention of sarcopenia. First,
proximal muscle weakness is a prominent feature of the clinical
syndrome of vitamin D deficiency. Second, VDR is expressed
in human muscle tissue, and VDR activation may promote de
novo protein synthesis in muscle (32). Third, several
observational studies suggest a positive association between 25-
hydroxyvitamin D and muscle strength or lower extremity
function in older persons (33, 34). Finally, in several double-
blind randomized controlled trials, vitamin D supplementation
increased muscle strength and balance (35, 36), and reduced the
risk of falling in community-dwelling individuals (36-38), as
well as in institutionalized individuals (35, 39). Notably, a
study by Glerup and colleagues suggest that vitamin D
deficiency may cause muscular impairment even before adverse
effects on bone occur (40).  
Mice without the VDR develop a skeletal muscle phenotype
with smaller and variable muscle fibers and persistence of
immature muscle gene expression during adult life (41). These
abnormalities persist after correction of systemic calcium
metabolism by a rescue diet (42).  
Vitamin D: desirable vitamin D status for better function
and lower risk of sarcopenia 
A dose-response relationship between vitamin D status and
muscle health was examined in NHANES III including 4100
ambulatory adults age 60 years and older. Muscle function
measured as the 8-foot walk test and the repeated sit-to-stand
test was poorest in subjects with the lowest 25-hydroxyvitamin
D (below 20 nmol/l) levels. Similar results were found in a
Dutch cohort of older individuals (33). Notably, while from the
smaller Dutch cohort a threshold of 50 nmol/l has been
suggested for optimal function (33), a threshold beyond which
function would not further improve was not identified in
NHANES III even beyond the upper end of the reference range
(> 100 nmol/l)[34] with a similar benefit by gender, level of
physical activity, and calcium intake. With respect to
sarcopenia, appendicular skeletal muscle mass was measured in
the Dutch cohort among 331 older adults using dual-energy x-
ray absorptiometry. After a 3-yr follow-up, and after
adjustment for physical activity level, season of data collection,
serum creatinine concentration, chronic disease, smoking, and
body mass index, persons with low (<25 nmol/l) baseline 25-
hydroxyvitamin D levels were 2.14 (0.73-6.33, based on
muscle mass) times more likely to experience sarcopenia,
compared with those with higher (>50 nmol/l) levels. The
associations were similar in men and women.  
Vitamin D: weakness / sarcopenia 
Muscle weakness is a prominent feature of the clinical
syndrome of vitamin D deficiency. Clinical findings in vitamin
D deficiency myopathy include proximal muscle weakness,
diffuse muscle pain, and gait impairments such as waddling
way of walking (43). The VDR is expressed in human muscle
tissue (44), and vitamin D bound to its nuclear receptor in
muscle tissue may lead to de novo protein synthesis (32, 45).
One uncontrolled biopsy trial in postmenopausal women with
osteoporosis documented a relative increase in the diameter and
number of type II muscle fibers after a 3 month treatment with
1-alpha-calcidiol (32). These findings were confirmed by three
recent double-blind RCTs with 800 IU vitamin D3 resulting in
a 4-11% gain in lower extremity strength or function (35, 36),
and an up to 28% improvement in body sway (36, 38) in older
adults age 65+ between 2 to 12 month of treatment.
VALIDATED TREATMENTS AND THERAPEUTIC PERSPECTIVES REGARDING NUTRITHERAPY
The Journal of Nutrition, Health & Aging©
Volume 13, Number 8, 2009
738
Vitamin D: fall prevention 
Summarizing 5 high-quality double-blind RCTs (n = 1237),
a meta-analysis published in 2004 found that vitamin D reduced
the risk of falling by 22% (pooled corrected OR = 0.78; 95% CI
[0.64, 0.92]) compared to calcium or placebo (46). This risk
reduction was independent of the type of vitamin D, duration of
therapy, and gender. For the two trials with 259 subjects using
800 IU of cholecalciferol per day over 2 to 3 months (35, 38),
the corrected pooled OR was 0.65 (95% CI [0.40, 1.00]) (46),
while 400 IU was insufficient in reducing falls (47). The
importance of dose of vitamin D in regard to anti-fall efficacy
was confirmed by one multi-dose double-blind RCT among
124 nursing home residents receiving 200, 400, 600 or 800 IU
vitamin D compared to placebo over a 5 month period (39).
Participants in the 800 IU group had a 72% lower rate of falls
than those taking placebo or a lower dose of vitamin D (rate
ratio=0.28; 95% confidence interval=0.11-0.75) (39).
Long-term supplementation over 3 years with 700 IU D3
plus 500 mg calcium among community-dwelling older women
reduced the odds of falling by 46% (OR = 0.54; 95%
confidence interval, 0.30-0.97) (37). Similarly, long-term
supplementation among institutionalized individuals with
ergocalciferol for 2 years, initially 10,000 IU given once
weekly and then 1,000 IU daily, reduced the incident rate ratio
for falling by 26% (RR = 0.73, 95% CI, 0.57-0.95) (48). A 49%
fall reduction among older individuals with a history of a fall
was demonstrated in a most recent 12-month trial with 1000 IU
ergocalciferol compared to placebo (OR = 0.61; 95%
confidence interval [CI], 0.37-0.99) (49).
The most up-to-date meta-analysis with a focus on anti-fall
efficacy from 8 high-quality double-blind RCTs of
supplemental confirms a benefit of vitamin D supplementation
on fall prevention at a dose of at least 700 IU vitamin D per day
(1).
Vitamin D: anti-fracture efficacy 
A 2009 meta-analysis of 12 double-blind RCTs for non-
vertebral fractures (n=42,279) and 8 RCTs for hip fractures (n =
40,886) found that anti-fracture efficacy of vitamin D is dose-
dependent and  increases significantly with a higher achieved
level of 25-hydroxyvitamin D in the treatment group starting at
75 nmol/l (2). No fracture reduction was observed for a
received dose of 400 IU or less per day, while a higher received
dose of 482 to 770 IU supplemental vitamin D per day reduced
non-vertebral fractures by 20% (pooled RR = 0.80; 95% CI,
0.72 -0.89; n = 33,265 from 9 trials) and hip fractures by 18%
(pooled RR = 0.82; 95% CI, 0.69 -0.97; n = 31,872 from 5
trials).  Notably, subgroup analyses for the prevention of non-
vertebral fractures with the higher received dose suggested a
significant benefit in all subgroups of the older population,
independent of dwelling, age and additional calcium
supplementation (see Table 1).  
Table 1
Non-vertebral fracture reduction with vitamin D based on
evidence from double-blind RCTs
Subgroups by received dose Fracture reduction
of vitamin D 
Pooled analysis from 3 trials with +2% Ø
low-dose vitamin D  (340-380 IU / day)
Pooled analysis from  9 trials with -20% Sig.
higher dose vitamin D (482-770 IU / day):
Pooled subgroup analysis from trials with 
higher  dose vitamin D (482-770 IE / Tag):
- Vitamin D2 -10% Ø
- Vitamin D3 -23% Sig.
- age 65-74 -33% Sig.
- - age 75+ -17% Sig.
- institutionalized 65+ -15% Sig.
- community-dwelling 65+ -29% Sig.
- Vitamin D plus Calcium  -21% Sig.
- Vitamin D main effects -21% Sig.
Legend: Adapted from Bischoff-Ferrari et al. Prevention of non-vertebral fractures with
oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch
Intern Med. 2009 Mar 23;169(6):551–61., Copyright© (2009), American Medical
Association (2). 
Vitamin D: dosing and safety 
Vitamin D intakes that may be required to achieve the
optimal levels of 25(OH)D in most individuals are not
established. Studies suggest that 700 to 1000 IU of vitamin D
per day may bring 50% of younger and older adults up to 75-
100 nmol/l (54-56). Thus, to bring most adults to the desirable
range of 75-100 nmol/l, vitamin D doses higher than 700-1000
IU would be needed. The current intake recommendation for
older persons (600 IU per day) may bring most subjects to 50-
60 nmol/l, but not to 75-100 nmol/l (27). A recent risk
assessment on vitamin D based on relevant, well-designed
human clinical trials of vitamin D documented the absence of
toxicity in trials conducted in healthy adults that used vitamin
D dose 10,000 IU vitamin D3 (57). The authors thus suggested
an upward adjustment of the safe upper limit from currently
2000 IU to 10,000 IU per day. Higher dose trials in older
populations using 2000 IU vitamin D per day are being
conducted for strength and fall endpoints. In clinical practice,
older adults or obese individuals often start treatment from
severe deficiency which requires higher doses of vitamin D to
achieve the shift into the adequate range of 25-hydroxyvitamin
D status (58, 59). In these situations a starting oral bolus of
30,000 to 100’000 IU once (60) followed by a daily or
intermittend regimen with vitamin D is useful. Monitoring of
25-hydroxyvitamin D levels may be ideal to ensure sufficient
vitamin D supplementation with a target range of 25-
hydroxyvitamin D between 75 to 100 nmol/l (9). With a half-
life of about 1.5 month, a control 25-hydroxyvitamin D serum
level after 6 weeks of treatment is valuable.  
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Vitamin D: Combination with Calcium 
Emerging data suggests that vitamin D may reduce falls and
fractures independent of additional calcium supplementation
provided the vitamin D intake is adequate (at least 800 IU per
day) and dietary calcium intake is between 700 to 800 mg per
day (2, 50, 51, 53). This is of clinical importance as calcium
supplementation is not well tolerated in older adults resulting in
low adherence to treatment (61).
Furthermore, with a lower minimal target for total calcium
intake of 700-800 mg per day (the recommended minimal
intake in the UK is 700 mg/day as oppose to 1200 mg in the
US), dietary requirements may be met by nutritional intakes
alone. Milk products could serve as a source of not only
calcium but also high-quality protein, which may be a
compelling strategy in the combat of sarcopenia if combined
with a vitamin D supplement (see protein section).
Vitamin D: summary and future research 
In summary, although RCT data regarding the vitamin D
effect on sarcopenia are missing, high-quality RCT data for
strength, balance, function, falls and fractures endpoints are
appealing and show a significant benefit of vitamin D at a dose
of at least 700 IU vitamin D per day. Additional data discussed
in this chapter linking vitamin D to sarcopenia prevention are
several:  the documented presence of the VDR in human
muscle tissue and its decline with age (62), prospective cohort
data that suggest a 2-fold increased risk of sarcopenia measured
by DEXA in older individuals with severe vitamin D deficiency
(63), uncontrolled trial data that suggest a relative increase in
type II muscle fibres with vitamin D treatment (32), and a clear
dose- reponse association between higher 25-hydroxyvitamin D
levels and lower extremity function from 2 epidemiologic
studies (33, 34).  
The dose-response relationships between higher doses of
vitamin D or higher achieved 25-hydroxyvitamin D levels on
the one hand and better function, greater fall and fracture
reduction on the other, suggest that higher doses of vitamin D
beyond 700-800 IU per day should be explored in future
research to optimize prevention of sarcopenia and its adverse
events. 
Protein: Its potential and complexities 
Daily consumption of protein declines with age, while there
is general agreement that a sufficient protein intake may
enhance muscle protein anabolism. A decrease in protein intake
is therefore viewed as a likely contributor to age-related
sarcopenia.  Importantly, several studies suggest that the
recommended daily allowance for protein may not be adequate
for older people to maintain skeletal muscle mass (64, 65).
Conceptually, the estimation of the RDA has several
limitations, one being that it was calculated based on nitrogen
balance studies, which is not a clinically relevant endpoint.
Another being that the data were collected among young men,
which may not extrapolate to older people who likely need a
higher protein intake to maintain their nitrogen balance (64).
However, even with the current target RDA of 0.8 g/kg*d for
all adults, between 15-38% of adult men and 27-41% of adult
women have dietary protein intakes below the RDA (64). 
Beyond the lack of long-term data, the complexity of a
higher protein recommendation among older persons are
several: one concern is that renal function declines with age and
high protein intake, particularly high intake of nondairy animal
protein, may accelerate renal function decline in those with
mild renal insufficiency (66). Some data also suggest that aging
impairs digestability and bioavailability of some protein
sources (67). For milk protein, protein gain was greater with
whey protein (rapidly digested protein), and lower with caseins
(slowly digested protein) in older men as opposed to younger
men where the pattern was inverse (67). 
Furthermore, it has been shown that other non-protein
energy sources, such as carbohydrates affect protein
metabolism, which may be most pronounced in older persons
(68). Finally, protein supplementation in older persons may
result in a compensatory decrease of voluntary food intake (69). 
These complexities and lack of longer-term data for
important clinical endpoints challenge future research in
sarcopenia prevention with higher protein intake (70). 
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